Quotient Clinical Completes Enabled FIH Program
Quotient Clinical has announced results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit.
Quotient Clinical has announced results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a highly selective small molecule c-Met tyrosine kinase inhibitor. The clinical phase, which was conducted under a single, adaptive protocol, was completed in only six months.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
